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INTRODUCTION
Cancer still ravages human lives. Survival rates 
of patients with advanced and metastatic cancers are 
in the range of 50 % (http://www.who.int/cancer).  This 
is the ultimate proclamation that we need to improve 
diagnostics, treatment and monitoring of cancer pa-
tients. These improvements are dependent on ad-
vances of fundamental and translational cancer re-
search.
The Ukrainian-Swedish workshop “New ap-
proaches in diagnostics and treatment of cancer” 
was the great opportunity to discuss some of the 
recent achievements. Variety of the research projects 
presented during the workshop was a good illustra-
tion of tackling the cancer problems from different 
directions. An important theme was highlighting the 
complexity of cancer, whether it is about mechanisms 
of tumorigenesis or novel treatments.
COMPLEXITY OF CANCER: REVISION 
OF THE ONCOGENES AND TUMOR 
SUPPRESSORS MODEL
Almost every day there is a publication describ-
ing a mechanism or a gene or a protein with explicit 
pro- or anti-tumorigenic activity. This raises a ques-
tion about what exactly triggers growth of a tumor. 
Apparently, the classical “oncogenes and tumor sup-
pressors” model of tumorigenesis may not be correct 
anymore. Today we have more than 100 genes, RNAs 
and proteins that showed a strong impact on breast 
cancer initiation and development. Majority of these 
components are not classical oncogenes or tumor 
suppressors (Fig. 1). The list of regulators with a strong 
impact on breast tumorigenesis includes scaffold pro-
teins (BRCA1, BRCA2, BRCA3), transcriptional factors 
(p53, eIEF-4E, c-myc), components of signaling path-
ways by EGF, TGFb, FGF, VEGF families (receptors and 
intracellular signaling molecules), steroid-dependent 
signaling, telomerase, cell cycle regulators, DNA 
damage response pathways, and regulators of meta-
bolic response [1, 2]. The cancer-related processes 
include cell proliferation, immortalization, cell death, 
migration, invasiveness, ability to form metastasis, 
to interact with non-malignant cells, ability to build 
a tumor, and escape of a tumor being recognized 
by the organism as a foreign body.
Complexity of tumorigenesis leads to conclusions, 
that the number of molecular cancer profiles may 
be significantly higher than is assumed today, and 
definitely much higher than the 5 molecular profiles 
predicted by a cohort study using mRNA microarrays 
[3]. A molecular cancer profile is defined as a set 
of molecules and activities that lead to initiation and 
growth of a tumor. As the same output, e.g. enhanced 
growth, may be achieved by changes in activities 
of different molecules, e.g. cyclins, CDKs, or CDK 
inhibitors, the number of combination of changed 
molecules may be higher than 100. Taking into account 
a combination of different cellular processes, such 
as cell proliferation, death, migration, invasiveness, im-
mune tolerance, etc, the number of molecular cancer 
profiles may be as high as 100.000.
Regulators with strong impact on breast tumorigenesis:
HER2 p53 Ras p27 PI3K BRCA1
AKT BRCA2 EIF-4E CHK2 Cyclin D1
ATM Cyclin E PTEN C-myc Rb
Regulatory processes and molecules strongly affecting tumori-
genesis:
Tyrosine Kinase receptor signaling (EOF, FGF, VEGF, PDGF) Serine/Threonine 
kinase receptor signaling (TGFbeta) Steroids (estrogen), Phosphatases, 
Metabolism regulators
Tumor-associated cells:
Immune response cells Fibroblasts, Endothelial cells, Adipocytes
Fig. 1. Tumorigenesis is regulated on different levels by a num-
ber of proteins and genes that are not typical oncogenes or tu-
mor suppressors. Selected genes, RNAs and proteins reported 
to have a strong impact on breast tumorigenesis are shown. 
Regulatory processes are also mentioned; specific components 
are not listed due to space limitation. Tumor-associated cells 
of importance for breast tumorigenesis are listed
SCIENTIFIC, MANAGERIAL AND 
TECHNOLOGICAL LIMITATIONS FOR 
CONTROLLING MOLECULAR CANCER 
PROFILES
The high number of potent regulators of tumori-
genesis raises the next question: Can we detect all 
molecular cancer profiles? To my opinion, we do not. 
The problem is in scientific, managerial and techno-
logical limitations.
The scientific limitations are in our incomplete 
knowledge of tumorigenesis. Constant reporting 
of new mechanisms of regulation of tumor growth is the 
best proof that a lot still has to be discovered. Especial-
ly pronounced this limitation is when to analyze studies 
of cancer proteome. Proteins are the main working 
entities of cells. To have a mutated oncogene does not 
mean that the person will get a cancer. The oncogene 
has to be expressed as a malfunctional protein to have 
an impact on cell functions. Thus, understanding 
Correspondence: Fax: +46-8-517 75000
 E-mail: serhiy.souchelnytskyi@ki.se
Abbreviations: BRCA1 — Breast Cancer susceptibility gene-1; 
EGF — epidermal growth factor; MALDI — matrix-assisted laser 
desorption/ionization; TGFb — transforming growth factor-b.
Exp Oncol 2011
33, 3, 166–169
Experimental Oncology 33, 166–169, 2011 (September) 167
of cancer proteome is of importance. Our observations 
and reports by others show that most of proteins have 
post-translational modifications (PTMs). The estimate 
is that more than 90% of proteins have at least one 
PTM. Today are known more than 300 PTMs of proteins 
that may create huge numbers of protein isoforms 
(www.abrf.org/index.cfm/dm.home?AvgMass=all). 
As an example, Fig. 2 shows a typical pattern 
of isoforms of a single protein with different patterns 
of O-phosphorylation. That means that the variability 
of proteins may be very large.
a b
Fig. 2. Multiple isoforms of a same protein: impact of post-
translational modifications. Images show inserts of 2D gels from 
tumor biopsies of patients that responded (a) or was resistant 
to a treatment (b). Arrows indicate a changed isoform. Lanes 
indicate the cluster of isoforms of the same protein with different 
pI. Proteins are enriched for O-phosphorylation
Modern physics, chemistry and biology indicate that 
our knowledge of biological systems is far from being 
complete. As an example, discovery that DNA may 
react on a spin moment suggests that DNA may have 
information-sensing capacity previously known only 
in physical systems [4]. For proteins, such phenomena 
have not been even studied. Another example is the 
lack of studies of N- and C-phosphorylation of proteins, 
despite that up to 50% of phosphoryl groups bound 
to proteins are N- or C-bound. This gap in signaling 
studies is most probably due to the lack of chemical 
methods to preserve, detect and analyze these PTMs. 
Even more astonishing example of how little we know 
is the fact that more than 30% of predicted by DNA 
or RNA sequencing proteins have not been cloned and 
studied. Thus, we are still scratching on the surface 
of biological mechanisms that govern cellular functions.
Domination of cohort-based approach in can-
cer studies is another hinder for individualization 
of anti-cancer treatment. Cohort-based approach, 
by definition, disregards individual difference between 
patients, and focuses on features common for a group 
of patients. As the focus is on specific genes, RNAs 
or proteins, and as exact components of the same reg-
ulatory process may be different in different patients, 
the cancer-related components will be disregarded 
in a cohort study as individual variations. To overcome 
this limitation, we proposed meta-data analysis that 
would preserve individual features [5]. Meta-data anal-
ysis is based on evaluation of cancer-related changes 
on the individual level, as a case-by-case study. The 
primary dataset of individual changes is then subjected 
to systemic analysis to unveil affected regulatory 
processes. And then these processes and affected 
proteins, genes and RNAs are compared between 
different patients. Application of meta-data analysis 
has been shown to be more informative in unveiling 
cancer-related changes on the individual level. This 
individualization made possible selection of drugs 
that would be suitable for the patient. In other words, 
cohort-based approach would propose that “if you 
have a marker/kinase A expressed, you may benefit 
from drug X, with the rate of success 70%”. Meta-data 
individualized approach would propose that “you have 
expression and activity of a kinase B, thus you will ben-
efit from a drug that inhibits kinase B”. The difference 
is between a possibility (“may” for cohort) and more 
secured assessment (“will” for individualized meta-
data). Meta-data approach provides individualization 
of assessment of molecular mechanisms governing 
tumorigenesis in a given patient. This allows truly in-
dividual tailoring of drugs and treatments.
Managerial limitations may originate due to the 
human psychology. Majority of scientists follow each 
other, and only few dare to take unexplored paths. 
Management of academic research does not promote 
high risk projects, even if such a risky project may 
be a breakthrough. Granting agencies prefer “safe 
cards” of established research fields. The joke that 
“new Albert Einstein would never get a grant today” 
is correct in the most of countries. As long as a cita-
tion index of a journal in which you publish your paper 
would have stronger impact on your granting success 
than the quality of your research, managerial issues 
would hamper scientific progress.
Technological limitations are going hand-in-hand 
with scientific ones. Many of the biological mecha-
nisms are not studied because the lack of technologies 
to discover them. In application to proteomics, tech-
nologies for comprehensive study of proteomes are 
not available and are under development. The prog-
ress in proteomics has been due to implementation 
of two-dimensional gel electrophoresis (2D-GE) and 
mass spectrometry (MS). Other electrophoretic and 
chromatographic techniques have not yet proven their 
superiority to 2D-GE and MS. However, 2D-GE has 
limited protein separation capacity, as it may allow de-
tection up to 3.000 proteins in a single 2D gel. MS is to-
day the most sensitive technology for identification 
of proteins, with identification of picomolar quantities 
of proteins. Femto- and attomolar levels of detection 
have been claimed, but they are rather exceptions 
than the routine performance of MS instruments. The 
main limitation of MS is its intrinsic inability to handle 
molecules of Mr more than 10.000 Da. Mass loss 
in larger proteins due to intramolecular interactions, 
isotopic composition and multiple ionization make 
informative MS analysis of proteins with Mr higher 
than 20.000 Da very difficult, if not an impossible task. 
What to expect? New technologies are under way, with 
3-tech for separation of proteins, and nanosequencing 
for identification of the proteins being two examples.
Similar situations are valid for studies of genome, 
transcriptome and metabolome. Deep sequencing 
technologies apparently make it possible to explore 
genome and transcriptome within reasonable quality, 
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time and efforts [6]. However, even deep sequenc-
ing technologies require amplification of targets and 
very extensive puzzling of information from short 
sequences. Metabolomics is in infancy, as the most 
informative technology, nuclear magnetic resonance 
(NMR), is only reaching required sensitivity to detect 
and identify molecules in at least nanomolar range.
Clear definition of what exactly scientific, mana-
gerial and technological limitations are is essential 
for finding clinical solutions. These limitations are 
interdependent, and progress in solving of one type 
of limitations stimulates progress in solving others.
WHAT CAN WE DO TODAY? AN EXAMPLE.
In clinics today, decision about selection of breast 
cancer treatment is based on imaging information 
(mammography, CT-scans, X-ray examinations), 
lymphnode status, metastasis detection, histo-patho-
logical description of a biopsy (histological description 
of a tumor, differentiation status, mitotic index, inflam-
mation and necrosis areas, etc), on immunohisto-
chemical evaluation of expression of Her2/neu, EGFR, 
ERa/ERb, PgR, E-cadherin, p53, VEGF and VEGF 
receptors. Here I would like to present an example 
of personalized approach to anti-cancer treatment that 
is applied in my laboratory and that was reported at the 
Workshop (Fig. 3). This approach is based on an indi-
vidual profiling of tumor proteomes, systemic analysis 
of cancer-related changes, building of an Individual 
Dynamic Response Network (Ind-DRNet), prediction 
of a set of drugs that would have tumor-killing impact, 
and transfer recommendations to an oncologist who 
will make final selection of a treatment.
Patient  Biopsy  Histo-pathological evaluation
 
Consultation with clinicians 
about selection of the most 
efficient scheme
Cancer Proteomics: protein extrac-
tion, 2D gel electrophoresis, identification 
of cancer-specific proteins
 
Identification of drugs that 
may destabilize the net-
work, and therefore may 
kill cancer cells.

Establishing of individual network signa-
ture (Ind-DRNet) and its analysis in the 
context of DRNet of immortalization, tu-
morigenesis, invasiveness, metastasis 
and response to drugs.
Fig. 3. The workflow of personalized treatment with application 
of proteomics technologies. The main steps in personalized as-
sessment of a patient are indicated and briefly described
Proposed Ind-DRNet approach incorporates histo-
pathological and biochemical diagnostics currently 
used in clinic. The main application of Ind-DRNets 
is to cancer cases when surgery is performed. That 
allows obtaining a biopsy for proteome profiling. When 
a patient underwent surgery, standard histo-patho-
logical and biochemical tests are performed. Then, 
a biopsy is used for proteome profiling in which tumor 
and adjacent histologicaly normal tissue are com-
pared. Extracted proteins are separated by 2D-GE, 
and image analysis is used to detect cancer-related 
proteins that are then identified by mass spectrom-
etry. To our experience, the number of cancer-related 
proteins is rather large and significantly different for 
different patients. Identified proteins are then used 
for building a patient-specific network that describes 
cancer-specific changes in a tumor of the patient. 
The networks provide also information about drug 
targets and applications of drugs to destroy the given 
tumor. An important value of the network is a pos-
sibility to predict whether certain drugs would kill the 
tumor or would just slow tumor growth. The network 
shows also which drugs may compensate and block 
each other and become less efficient, which drugs 
would have an additive effect, and which drugs would 
synergize in their anti-cancer action.
When considering use of a certain drug, an oncolo-
gist would have to consider whether drug target is ex-
pressed and is active, specificity, pharmacokinetics/
pharmacodynamics of the drug, possible off-target ef-
fects, compensatory mechanism that can block action 
of the drug, and any systemic effects of a combined 
use of the drug with other therapeutics. This is a lot 
to think about. Can clinicians be helped? Here I present 
2 examples of how proteomics can help with analysis 
of specificity (1st example) and clinical application (2nd 
example) of the type I TGFβ receptor (TβR-I) kinase 
inhibitor. This inhibitor is a prototype of a drug in clini-
cal trials. These examples were also presented during 
the Workshop.
TβR-I inhibitor, an imidazole-based compound 
SB431542, was claimed to be “highly specific” [7]. 
However, in clinical trials the drug showed side effects 
on cardio-vascular system. Our proteomics-based 
analysis showed that more than 20 kinases could 
be inhibited by this compound. Why these kinases 
were not detected earlier, before clinical trials? The 
answer is that the company used traditional approach, 
with more than 40 kinases tested. However, the hu-
man kinome consists of more than 400 kinases [8]. 
Thus, missing to perform unbiased test of all kinases 
may be quite expensive, when off-targets would lead 
to drug-prohibiting side effects.
When inhibition of TGFβ signaling would be ben-
eficial? An answer to this question can be provided 
by proteomics and immunohistochemistry (IHC) 
(Fig. 4). Proteome profiling and systemic analysis fol-
lowed by building of Ind-DRNets for 4 patients showed 
that 2 patients (#6 and #47) have over-activated TGFβ 
signaling in tumors [5]. Validation tests of TβR-I activ-
ity on its substrate Smad2 showed by IHC that cases 
#6 and #45 had enhanced Smad2 phosphorylation. 
This conclusion indicated that the patient #1 would 
not benefit from TβR-I inhibition (no TGFβ signaling 
over-activation as by proteomics and IHC), while pa-
tient #6 may have a positive response (over-activation 
by proteomics and IHC). What about patients #45 and 
#47? Both showed indications that TGFb signaling 
may be over-active, but 2 tests gave not fully comple-
mentary results. In this situation, the network analysis 
allowed to make a decision. Ind-DRNets of these pa-
tients showed that the TβR-I inhibition may be benefi-
cial if at the same time inhibition of steroid-dependent 
and EGF family-dependent signaling would be done 
for patient #45. For patient #47, TβR-I inhibition would 
have to be combined with inhibition of inflammatory 
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responses [5]. Therefore, the use of TβR-I inhibitors 
would be tailored to each of the patients.
Case 1
Weak
+
Case 6
Considerable
+++
Case 45
Weak
+
Case 47
Considerable
+++
Activity
of TGFβ
(by proteo-
mics)
IHC
pSmad2
reﬂects
TbR-l
activity
+
No
+++
Yes
+++
Combine
 with Tmx
Iressa/Herceptin
++
Inhibit
Inﬂammatory/
Immune
response
Shall
the drug
be used?
Fig. 4. Selection of patients who would respond to treatment 
with TβR-I kinase inhibitor. Results of proteome profiling of tumor 
biopsies and immunohistochemistry staining for activated/phos-
phorylated Smad2 are indicated. IHC images for phosphorylated 
Smad2 staining are shown.  In the lower part, there are recom-
mendations for use of the TβR-I kinase inhibitor
OUTLOOK
Cancer can be treated. It is only a matter of time 
when cancer will not be anymore a terminal disease. 
Two main parallel roads are ahead. The first is continued 
progress of fundamental and translational research. 
The second is understanding that biomedicine requires 
help from other fields, such as mathematics, computer 
sciences, chemistry, physics and engineering.
However, even today we have accumulated suf-
ficient knowledge and experience to help patients. 
Early detection, improved diagnostics and especially 
tailoring of drugs to patients are realistic, and are used 
in clinics. We need further development of technolo-
gies for a single-molecule sequencing, comprehensive 
separation of proteins and metabolites, and introduc-
tion of high throughput assays for testing individual pa-
tients. These developments would be complemented 
by novel non-invasive diagnostic tools. The workshop 
highlighted many of the tasks to be solved, and also 
showed how solutions are developing.
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